XVIVO

Xvivo Perfusion

Market Cap 2,344.0M

Xvivo Perfusion is a medtech company focused on the area of transplantation. The company was a part of Vitrolife until 2012 when it was spun off and listed at First North. Marketed products focus on the area of lung transplantation, where the company's product Perfadex currently holds a dominant position in the market for cold preservation solutions used prior to lung transplants. The company has also launched a STEEN Solution and the XPS which are used for warm perfusion of lungs.   The acquisition of Vivoline in 2016 strengthens the company's position in the area of lung transplantation and also meant that the research portfolio was broadened to heart transplantation. Furthermore, Xvivo Perfusion has a research portfolio with projects within liver and heart transplantation and isolated tissue therapy. Xvivo Perfusion work with distributors on some markets, but the relatively few clinics enable the company to cost-effectively establish business relations with the customers in the most important markets. In 2016, the company had about SEK 120 million in revenues in 2016 and an EBITDA margin of 11.5 percent. 

+ more

Redeye Research

Reports

Notes

Today
Day High
90.75
90.25
Day Low
88.50
Day Open
89.00
Prev Close
89.50
VWAP
90.2
Volume
7K
Turnover
0.628M
Top Broker
ENS
VWAP
89.4
Avg Volume
10K
Avg Turnover
0.895M
Top Brokers
ENS/AVA
VWAP
92.0
Avg Volume
18K
Avg Turnover
1.678M
Top Brokers
AVA/NON
VWAP
88.4
Avg Volume
20K
Avg Turnover
1.767M
Top Brokers
AVA/NON
52 week summary
Price Range
77.8
Last
108.0
Beta
N/A
Market Cap
2,344.0M
Total Return
14.1%
Trailing P/E
-8,823.5
Div Yield
0.0%
Shares Outstanding
26.2M
Next Earnings Date
9 Feb
Stock Exchange
NASDAQ Stockholm
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.


Relative Price Strength
Change 3 Months -8.7%
Change 12 Months 4.3%
Volume Trend
Average Volume 10 vs 60 Days -54.5%
Price VS
52 Week High -16.4%
50 Day Moving Average -0.4%
200 Day moving Average -4.5%

Add article markers

Compare Xvivo Perfusion to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
  • Management
  • Magnus Nilsson, CEO
  • Christoffer Rosenblad, CFO
  • Executive board
  • Fredrik Mattson, Chairman of the board
  • Gösta Johannesson
  • Folke Nilsson
  • Semmy Rülf
  • Erik Von Schenk
  • Camilla Öberg
Last updated: 2017-03-31 Source: Redeye
Major Owners Equity Votes
Bure Equity 18.7%
18.7%
Eccenovo AB 5.5%
5.5%
Swedbank Robur Fonder 5.5%
5.5%
Fjärde AP Fonden 4.2%
4.2%
Norron Fonder 3.7%
3.7%
Thomas Olausson 3.5%
3.5%
Handelsbanken Liv Försäkring AB 2.6%
2.6%
Nordnet Pensionsförsäkring 2.4%
2.4%
Avanza Pension 2.1%
2.1%
Tredje Ap-Fonden 1.5%
1.5%
Last updated: 2017-07-27 Source: Redeye/Holdings
Timeframe Transactions Net Shares
Last 12 weeks
0 Purchases
+ 0
0 Sales
- 0
Last 24 weeks
0 Purchases
+ 0
0 Sales
- 0
Report Date Name Position Transaction Shares Chg Est Value (SEK)

Catalyst Potential is behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Source: Millistream FI
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(SEKm)
  • Capital employed(SEKm)
  • Capital turnover rate
  • (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow
  • 2014
  •  
  • 3.8%
  • 5.3%
  • 7.6%
  • 13.5%
  • 8.8%
  • 6.2%
  •  
  • 0.24
  • 0.24
  • 0.00
  •  
  • 21.7
  •  
  • 696.4
  • 142.7
  • 142.7
  • 8.8
  • 8.2
  • 61.0
  • 93.0
  • 4.2
  •  
  • 89.3%
  • 0.0%
  • -48
  • 130
  • 0.4
  • 2014
  •  
  •  
  • 48
  • 19
  • 26
  • 0
  • 93
  •  
  • 1
  • 0
  • 0
  • 4
  • 0
  • 97
  • 0
  • 102
  • 5
  • 200
  •  
  •  
  • 0
  • 15
  • 0
  • 15
  • 0
  • 0
  • 0
  • 15
  • 3
  • 4
  • 178
  • 0
  • 178
  • 200
  • 2014
  • 85
  • -73
  • -4
  • 7
  • 0
  • 7
  • 4
  • 11
  • -17
  • -13
  • -26
  • 2014 Q4
  • 26
  • -22
  • 3
  • -3
  • 0
  • 0
  • 1
  • 0
  • 0
  • 0
  • 1
  • -0
  • 0
  • 2015
  •  
  • 2.8%
  • 4.1%
  • 5.5%
  • 15.6%
  • 6.0%
  • 4.3%
  •  
  • 0.24
  • 0.24
  • 0.00
  •  
  • 21.5
  •  
  • 1,217.3
  • 245.2
  • 245.2
  • 10.5
  • 10.1
  • 64.7
  • 168.8
  • 6.8
  •  
  • 90.5%
  • 0.0%
  • -41
  • 144
  • 0.6
  • 2015
  •  
  •  
  • 41
  • 26
  • 29
  • 0
  • 96
  •  
  • 7
  • 0
  • 0
  • 4
  • 0
  • 93
  • 0
  • 104
  • 4
  • 204
  •  
  •  
  • 0
  • 14
  • 0
  • 14
  • 0
  • 0
  • 0
  • 14
  • 2
  • 4
  • 185
  • 0
  • 185
  • 204
  • 2015
  • 120
  • -101
  • -12
  • 7
  • 0
  • 7
  • 12
  • 19
  • -11
  • -14
  • -8
  • 2015 Q1
  • 32
  • -29
  • 3
  • -3
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • -0
  • -0
  • 2015 Q2
  • 29
  • -25
  • 5
  • -3
  • 0
  • 0
  • 2
  • 0
  • -0
  • 0
  • 2
  • -1
  • 1
  • 2015 Q3
  • 27
  • -22
  • 4
  • -3
  • 0
  • 0
  • 2
  • 0
  • 0
  • 0
  • 2
  • -1
  • 1
  • 2015 Q4
  • 33
  • -26
  • 7
  • -3
  • 0
  • 0
  • 4
  • 0
  • -0
  • 0
  • 4
  • -1
  • 3
  • 2016
  •  
  • 0.4%
  • 0.8%
  • 1.9%
  • 11.5%
  • 2.0%
  • 1.1%
  •  
  • 0.07
  • 0.07
  • 0.00
  •  
  • 22.6
  •  
  • 1,782.9
  • 1,323.1
  • 1,323.1
  • 14.4
  • 12.9
  • 111.8
  • 652.1
  • 4.0
  •  
  • 93.8%
  • 0.0%
  • -203
  • 292
  • 0.3
  • 2016
  •  
  •  
  • 203
  • 36
  • 35
  • 0
  • 274
  •  
  • 15
  • 0
  • 0
  • 66
  • 0
  • 158
  • 0
  • 239
  • 15
  • 527
  •  
  •  
  • 0
  • 30
  • 0
  • 30
  • 0
  • 0
  • 0
  • 30
  • 0
  • 3
  • 495
  • 0
  • 495
  • 528
  • 2016
  • 138
  • -122
  • -13
  • 3
  • 0
  • 3
  • 13
  • 16
  • -1
  • -148
  • -17
  • 2016 Q1
  • 34
  • -29
  • 5
  • -3
  • 0
  • 0
  • 2
  • 0
  • -0
  • 0
  • 2
  • -1
  • 1
  • 2016 Q2
  • 34
  • -30
  • 5
  • -3
  • 0
  • 0
  • 2
  • 0
  • 0
  • 0
  • 2
  • -1
  • 2
  • 2016 Q3
  • 32
  • -29
  • 3
  • -3
  • 0
  • 0
  • -1
  • 0
  • 0
  • 0
  • -1
  • 0
  • -1
  • 2016 Q4
  • 38
  • -35
  • 4
  • -4
  • 0
  • 0
  • 0
  • 0
  • -0
  • 0
  • -0
  • -0
  • -1
  • 2017 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2017 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2017 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2017 Q1
  • 37
  • -34
  • 4
  • -4
  • 0
  • 0
  • 0
  • 0
  • -0
  • 0
  • -0
  • -0
  • -0
  • 2017 Q2
  • 37
  • -31
  • 6
  • -4
  • 0
  • 0
  • 2
  • 0
  • -0
  • 0
  • 2
  • -1
  • 1
  • 2017 Q3 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2017 Q4 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 Q1 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 Q2 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 Q3 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2018 Q4 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 Q1 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 Q2 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 Q3 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • 2019 Q4 E
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Estimated Values is behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Last updated: 2017-11-15 Source: Redeye
Source: Redeye

Presentations, research interviews and videos from our events listed here.


Source: Redeye

When selecting comparable companies, we try to group companies that are in the same or similar sector or subsector. But, more important, have growth, margins and risk characteristics similar to the company being valued.